Forticell Bioscience Inc fka FORBQ

[MWM]

Corporate Overview Features


Founded in 1991 to develop a tissue- engineered product now known as OrCel®

Publicly traded company since 1996

Raised nearly $150 million to fund R&D

Fully integrated organization -- approximately 40 employees

FDA approved cGMP

FDA approved cGMP pilot manufacturing facility

Initial focus on treatment of acute and chronic wounds - granted two FDA product approvals for non-cryopreserved OrCel®